SavedAdd your journal

Journals / Journal of Clinical and Analytical Medicine / 2015 / Cilt: 6 - Sayı: 3

Prostat spesifik antijen 4 ng/ml nin altındaki hastalarda prostat biyopsi sonuçlarımız

Our prostate biopsy results in the patients with prostate specifc antigen levels below 4 ng/ml

Hasan Salih SAĞLAM
Hüseyin AYDEMİR
Öztuğ ADSAN
Şükrü KUMSAR
Osman KÖSE
Salih BUDAK
Pages
320–323
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Accordingto our results, signifcant number of cancers can be detected in PSA below4 ng/ml levels.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The aim of this study is to evaluate the re¬sults of prostate biopsy ofpatients who had the prostate-specifc antigen (PSA) levels below 4 ng/ml.Material and Method: The medical records of 524 pa¬tients who underwenttransrectal prostate biopsy be¬tween January 2010 and February 2013 in ourclinic, due to suspi¬cion of prostate cancer were evaluated and histopathoogic results of 43 patients whose PSA levels under 4 ng/ml were retrospectively revieved.
📊
Key Findings & Data:Results: The mean age of patients was 64.63 ±7:42 and themean level of PSA was 2.89 ±0.88ng /ml.
💡
Conclusion & Impact:Accordingto our results, signifcant number of cancers can be detected in PSA below4 ng/ml levels.
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: The aim of this study is to evaluate the re¬sults of prostate biopsy ofpatients who had the prostate-specifc antigen (PSA) levels below 4 ng/ml.Material and Method: The medical records of 524 pa¬tients who underwenttransrectal prostate biopsy be¬tween January 2010 and February 2013 in ourclinic, due to suspi¬cion of prostate cancer were evaluated and histopathoogic results of 43 patients whose PSA levels under 4 ng/ml were retrospectively revieved. Results: The mean age of patients was 64.63 ±7:42 and themean level of PSA was 2.89 ±0.88ng /ml. A digital rectal examination (DRE)had suspicious fndings in 41(95.34%) patients. Prostate adenocarcinomawas determined in 13 of (30.23%) patients according to the biopsy result.The mean PSA value of these patients was 2.89 ±0.88 ng/ml and the meangleason score of these patients was 6.41 ±0.87. The mean prostate volumeof these patients was 41.46 ±11.95 cm3. Discussion: In our study, prostatecancer was identifed in 30.3% of patients whose PSA levels were below 4ng/ml. DRE, is still important for the evaluation of the prostate. Accordingto our results, signifcant number of cancers can be detected in PSA below4 ng/ml levels.

Özet

Amaç: Bu çalışmada kliniğimizde prostat spesifik antijen (PSA) 4 ng/ml ve altında değerlere sahip hastaların transrektal ultrasonografi (TRUS) eşliğindeyapılmış olan prostat biyopsilerinin histopatolojik sonuçlarının değerlendirilmesi amaçlandı. Gereç ve Yöntem: Kliniğimizde Ocak 2010-Şubat 2013 tarihleri arasında prostat kanseri şüphesi nedeniyle prostat biyopsisi yapılan 524hastadan PSA değerleri 4 ng/ml ve altında olan 43 olgu histopatolojik sonuçları ile retrospektif olarak değerlendirildi. Bulgular: Hastaların yaş ortalaması 64.63 ±7.42 olup ortalama PSA değeri 2.89 ±0.88 ng/ml idi. Hastaların 41(%95.34) inde parmakla rektal muayenede (PRM) şüpheli bulgu vardı. Hastaların biyopsi sonucunda 13 (%30.23) hastada prostat adenokarsinom tespit edildi. Bu hastaların ortalama PSA değerleri 2.52 ±1.21 ng/ml olup ortalama gleason skorları ise 6.41 ±0.87 idi. Ortalama prostat volümleri 41.46±11.95 cm3 olarak tespit edildi. Tartışma: Çalışmamızda PSA 4 ng/mlnin altında %30.3 oranında prostat kanseri saptanmıştır. PRM, prostat değerlendirilmesinde halen önemini korumaktadır. Sonuçlarımız PSA 4 ng/mlnin altındaanlamlı sayıda kanser tespit edildiğini göstermektedir.

🔖

Cite This Article

SAĞLAM, H. S., AYDEMİR, H., ADSAN, Ö., KUMSAR, Ş., KÖSE, O., BUDAK, S. (2022). Prostat spesifik antijen 4 ng/ml nin altındaki hastalarda prostat biyopsi sonuçlarımız. Journal of Clinical and Analytical Medicine, Cilt: 6 - Sayı: 3, 320–323. https://ajindex.com/articles/561100

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Polascik TJ, Oesterling JE,Partin AW. Prostate specific antigen: a decade of discovery what we have learned and where we are going. J Urol 1999;162:293-306
  2. Heidenreich A, Bastian PJ, Bellmunt J,M. Bolla,S. Joniau, T.H. van der Kwast, et al. Guidelines on Prostate Cancer. EAUPG 2013;41-59
  3. Ballentine CH, Peter CA, Michael JB, Ruth E, Stephen JF, Kirsten LG, et al. Early detection of prostate cancer. American Urological Association (AUA) Guideline. J Urol 2013;190(2):419-26
  4. Sandblom G, Varenhorst E, Rosell J, Löfman O, Carlsson P. Randomised prostate cancer screening trial: 20 year follow up. BMJ 2011;342:1539
  5. Catalona WJ, Loeb A. The PSA era is not over for prostate cancer. Eur Urol 2005;48:541-5
  6. Catalona WJ, Smith DS, Ratlif TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61
  7. Cooner WH, Mosley BR, Rutherford CL, Beard JH, Pond HS, Terry WJ et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990;143:1146-52
  8. Catalona WJ, Hudson MA, Scardino PT. Selection of optimal prostate specific antigen cutofs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994;152:2037-42
  9. Thompson IM, Pauler DK, Goodman PJ. Prevalence of prostate cancer among menwith a prostate specific antigen level _____ 4.0 ng per milliliter. N Engl J Med 2004;350(2):2239–46
  10. Gilbert SM, Cavallo CB, Kahane H, Lowe FC. Evidence suggesting PSA cutpo- int of 2.5 ng/mL for prompting prostate biopsy: review of 36,316 biopsies. Uro- logy 2005;65:54953
  11. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, DownsJ. The prostate specific antigen era in the United States is over for prostate cancer: what happe- ned in the last 20 years? J Urol 2004;172:1297-01
  12. Jang TL, Han M, Roehl KA, Hawkins SA, Catalona WJ. More favorable tumor fe- atures and progression free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific efects. Urology 2006;67:343-8
  13. Zhu H, Roehl KA, Antenor AV, Catalona WJ. Biopsy of men with PSA level of 2.6 to 4.0 ng/ml associated with favorable pathologic features and PSA progression rate: a preliminary analysis. Urology 2005;66:547-51
  14. Yossepowitch O, Eggener SE, Bianco FJ Jr, Carver BS, Serio A, Scardino PT et al. Radical prostatectomy for clinica